National Newspaper Ad Hits Genentech’s Specialty-Drug Switch

by Admin | November 24, 2014 4:54 pm

November 24, 2014—A leading hospital group purchasing organization and 16 prominent health care institutions asked Genentech in an open letter in The New York Times yesterday to reverse its “ill-advised decision” to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the more expensive specialty distribution channel.  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/11/national-newspaper-ad-hits-genentechs-specialty-drug-switch/

Copyright ©2026 340binformed.org unless otherwise noted.